Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

DUBLIN, June 5, 2023 /PRNewswire/ — Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with Peyronie’s disease (PD) were published by peer-reviewed journal Urology®. Read the article here. “The data analysis points to the importance … Read more

Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials

Only ready-to-use (RTU) liquid format of bivalirudin expected to begin shipping in summer 2023 RTU bivalirudin injection does not require reconstitution, dilution or mixing, which helps increase efficiency for hospitals and healthcare providers DUBLIN, May 24, 2023 /PRNewswire/ — Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement … Read more